title: Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis.
authors.forename: G
authors.initials: G
authors.lastname: Mase
authors.forename: M
authors.initials: M
authors.lastname: Zorzon
authors.forename: E
authors.initials: E
authors.lastname: Biasutti
authors.forename: B
authors.initials: B
authors.lastname: Vitrani
authors.forename: G
authors.initials: G
authors.lastname: Cazzato
authors.forename: F
authors.initials: F
authors.lastname: Urban
authors.forename: M
authors.initials: M
authors.lastname: Frezza
mesh_terms: D002908:Chronic Disease; D020022:Genetic Predisposition to Disease; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000235:genetics; D011994:Recombinant Proteins
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins